InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
4
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+4.6%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Casdin Eli, Director. Officer active across 8 companies, notably GeneDx Holdings Corp.. Aggregated, 37 filings have been recorded. Split: 4 buys · 0 sell. Total volume traded: €73.3m. History available since 22 July 2021. The latest transaction was disclosed on 18 June 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations37 total
99,116 sharesCommon StockSEC:0001193125-26-279828:0
3,576 sharesClass A Common StockSEC:0001534264-26-000002:0
12,924 shares0Class A Common StockSEC:0000919574-25-004391
12,924 shares0Class A Common StockSEC:0000919574-25-004391:0
1,588 shares0Common StockSEC:0000950170-24-085790:0
43,128 shares0Common StockSEC:0000950170-24-080723:0
5,828 shares0Class A Common StockSEC:0001415889-24-018070:0
22,800 shares@ US$2.5010.8% of flowCommon StockSEC:0000950170-24-018893:0
3,807 sharesCommon StockSEC:0001104659-24-002655:0
3,430 sharesCommon StockSEC:0001209191-24-001324:0
8,659,372 shares0Common StockSEC:0000919574-23-006265:0
26,376 shares0Common StockSEC:0001162194-23-000048:0
250,000 shares@ US$1.886289.2% of flowCommon StockSEC:0000919574-23-003426:0
Ideal exit: 11 Feb 2024 (T+270)
45,454 shares0Class A Common StockSEC:0001209191-23-027315:0
3,430 shares0Common StockSEC:0001213900-23-021841:0
71,428,542 shares@ US$0.35100.0% of flowClass A Common StockSEC:0000899243-23-003400:0
Ideal exit: 28 Oct 2023 (T+270)
215,193 sharesClass A Common StockSEC:0000919574-22-007074:0
2,492,042 shares@ US$2.60100.0% of flowCommon StockSEC:0000919574-22-006902:0
Ideal exit: 14 Aug 2023 (T+270)
30,914 shares0Common StockSEC:0001162194-22-000076:0
12,836 sharesClass A Common StockSEC:0001209191-22-028687:0
11,437,500 shares@ US$4.00100.0% of flowClass A Common StockSEC:0001213900-22-023579:0
Ideal exit: 24 Jan 2023 (T+270)
15,852 shares0Common StockSEC:0000950142-22-001324:0
3,430 shares0Common StockSEC:0001062993-22-006752:0
8,659,372 sharesClass A Common StockSEC:0000899243-21-049720
8,659,372 sharesClass A Common StockSEC:0000899243-21-049720:0
25 of 37 declarations
About Casdin Eli
Casdin Eli is a Director of Standard Biotools INC., GeneDx Holdings Corp., SomaLogic, Inc., Sema4 Holdings Corp., and Tenaya Therapeutics, Inc. He has made 37 filings in total, all sampled recently. During this period, he has made purchases totaling 73262162 EUR, with no sales. His most significant filings include a purchase of 43554000.12 EUR in Sema4 Holdings Corp. on May 3, 2022, and a purchase of 23039991.07 EUR in GeneDx Holdings Corp. on February 2, 2023.
